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Association of receptor activity-modifying proteins
(RAMP1-3) with the G protein-coupled receptor
(GPCR) calcitonin receptor-like receptor (CLR) en-
ables selective recognition of the peptides calcitonin
gene-related peptide (CGRP) and adrenomedullin
(AM) that have diverse functions in the cardiovascu-
lar and lymphatic systems. How peptides selectively
bind GPCR:RAMP complexes is unknown. We report
crystal structures of CGRP analog-bound CLR:
RAMP1 and AM-bound CLR:RAMP2 extracellular
domain heterodimers at 2.5 and 1.8 A˚ resolutions,
respectively. The peptides similarly occupy a shared
binding site on CLR with conformations character-
ized by a b-turn structure near their C termini rather
than the a-helical structure common to peptides
that bind related GPCRs. The RAMPs augment the
binding site with distinct contacts to the variable
C-terminal peptide residues and elicit subtly different
CLR conformations. The structures and accompa-
nying pharmacology data reveal how a class of
accessorymembrane proteinsmodulate ligand bind-
ing of a GPCR and may inform drug development
targeting CLR:RAMP complexes.
INTRODUCTION
G protein-coupled receptors (GPCRs) are a large family of cell
surface receptors that regulate a multitude of biological pro-
cesses in response to a diverse array of stimuli and they are
important drug targets. The class B/Secretin family GPCRs in
humans include 15 receptors that are activated by diverse neu-
ropeptides, peptide paracrine factors, and peptide endocrine
hormones (Hoare, 2005). These receptors are less well under-stood than the larger class A/Rhodopsin family, despite their
physiological and clinical importance. Class B GPCRs comprise
an extracellular domain (ECD) of about 120 amino acids in addi-
tion to the 7-transmembrane (7TM) domain in the membrane.
The ECD has an N-terminal a-helix and a set of b sheets held
together by three disulfide bonds (Archbold et al., 2011). Pep-
tides bind class B GPCRs via a ‘‘two-domain’’ model whereby
their C-terminal region binds the ECD and their N-terminal region
binds and activates the 7TMdomain. Crystal structures are avail-
able for class BGPCRECDswith bound peptides related to PTH,
CRF, GIP, and GLP-1 (Pal et al., 2010; Parthier et al., 2007; Pios-
zak et al., 2008, 2009; Pioszak and Xu, 2008; Runge et al., 2008;
Underwood et al., 2010) and a consensus has emerged from
these studies. The peptides bind as extended a helices to the
same region of the receptor, in a groove between the N and C
termini of the isolated ECDs. For PTH, GIP, and GLP-1 families,
the peptides are closest to the N terminus; for the CRF-related
peptides, they are displaced to be closer to the C terminus.
Although this model of binding is valid for several class B
GPCRs, it cannot apply to all class B receptors. In particular,
there are problems understanding the binding of members of
the calcitonin (CT) family of peptides; calcitonin gene-related
peptides alpha and beta (aCGRP, bCGRP), adrenomedullin
(AM), adrenomedullin 2/intermedin (AM2), amylin (Amy), and
CT (Hong et al., 2012; Poyner et al., 2002). These C terminally
amidated peptides have a range of actions including neurogenic
inflammation (CGRP), vasodilation/cardioprotection (CGRP,
AM, and AM2), and regulation of blood and lymphatic vascular
development (AM), nutrient intake and blood glucose (Amy),
and bone turnover (CT). CGRP antagonists showed promise
for the treatment of migraine and AM may be of value for the
treatment of cardiovascular disorders (Durham and Vause,
2010; Karpinich et al., 2011). An Amy analog is used to treat in-
sulin-dependent diabetes patients (Edelman et al., 2008) and
CT has been long used to treat bone disorders (Purdue et al.,
2002).
CGRP, AM, and AM2 binding to their cognate class B recep-
tor, the calcitonin receptor-like receptor (CLR), is dependentMolecular Cell 58, 1–13, June 18, 2015 ª2015 The Authors 1
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proteins that determine ligand selectivity; receptor activity-modi-
fying proteins (RAMPs) 1, 2, or 3 (Hong et al., 2012; McLatchie
et al., 1998). RAMPs have an ECD of about 100 amino acids
and a single TM segment (Parameswaran and Spielman, 2006).
CLR:RAMP1 is aCGRP receptor, CLR:RAMP2 preferentially rec-
ognizes AM and is called the AM1 receptor, and CLR:RAMP3
binds both AM and AM2 with high affinities and is called the
AM2 receptor. Amy by itself has a low affinity for the class B
CT receptor (CTR); however, when CTR associates with any of
the RAMPs, its affinity for Amy is markedly increased (Christo-
poulos et al., 1999; Poyner et al., 2002). CTR alone is the receptor
for CT. Thus, the RAMPs profoundly alter the behavior of CLR
and CTR. Although RAMPs are best characterized for their ef-
fects on CLR/CTR, they also interact with several other class B
GPCRs and with certain class A/Rhodopsin and class C/Gluta-
mate family GPCRs, making it particularly important to under-
stand the molecular basis for RAMP actions (Bouschet et al.,
2005; Lenhart et al., 2013; Wootten et al., 2010). RAMPs provide
an excellent opportunity to explore how accessory membrane
proteins can modulate GPCR pharmacology.
Crystal structures are available for ligand-free and small
molecule antagonist-bound CLR:RAMP1 and ligand-free CLR:
RAMP2 ECD complexes, but these provide little insight into
how peptides bind or how RAMPs determine selectivity (Kusano
et al., 2012; ter Haar et al., 2010). Extensive mutagenesis on the
RAMPs (Qi and Hay, 2010) only provided clear evidence for the
involvement of one RAMP residue (RAMP1 W84) in the binding
of CGRP and two residues (RAMP2 F111 and E101) for AM
binding (Moore et al., 2010; Watkins et al., 2014). It has not
been possible to interpret these data mechanistically. A further
complication is that it appears unlikely that CGRP and AM bind
as extended helices as seen with other class B peptide ligands;
there is evidence that only a small portion of these peptides form
a helices and that at their C termini, there are one or more turn
structures (Breeze et al., 1991; Carpenter et al., 2001; Pe´rez-
Castells et al., 2012; Watkins et al., 2013b). Consequently, the
mechanism of RAMPaction and themode of binding of CT family
peptides remain unknown. Here, we describe high-resolution
crystal structures of CGRP analog-bound CLR:RAMP1 and
AM-bound CLR:RAMP2 ECD heterodimers that reveal bound
peptide conformations starkly different from other class B
GPCR peptide ligands, explain how RAMPs determine peptide
selectivity, and providemolecular templates to guide drug devel-
opment targeting CLR:RAMP complexes.
RESULTS
Engineering CLR:RAMP ECD Complexes for
Crystallization
Wepreviously reported a tethered fusion protein approach to en-
gineer the CLR:RAMP1 and CLR:RAMP2 ECD complexes for
crystallization (Moad and Pioszak, 2013), inspired by previous
successes usingmaltose binding protein (MBP) as a ‘‘crystalliza-
tion module’’ for class B GPCR ECDs (Kumar et al., 2011;
Pal et al., 2010; Pioszak et al., 2008, 2009, 2010; Pioszak and
Xu, 2008). MBP-RAMP1 or MBP-RAMP2 ECD-CLR ECD fusion
proteins in which the two ECDs were covalently tethered with a2 Molecular Cell 58, 1–13, June 18, 2015 ª2015 The Authorsflexible (Gly-Ser)5 linker were designed to ensure complex sta-
bility and enforce 1:1 CLR:RAMP stoichiometry. The tethered
RAMP1-CLR ECD fusion was a monomer, whereas the tethered
RAMP2-CLR ECD fusion purified as a dimer, but the physiolog-
ical relevance of oligomerization is unknown. Both proteins
selectively bound their respective peptides but failed to yield
crystals in the presence of peptides.
We reasoned that tether flexibility and oligomerization of the
AM1 receptor ECD complex hindered the crystallization efforts.
We produced new constructs with a (Gly-Ser-Ala)3 tether de-
signed to decrease flexibility and we identified a single amino
acid substitution in the RAMP2 ECD, L106R, which prevented
dimerization of the tethered RAMP2-CLR fusion protein (Fig-
ure S1A) by disrupting a putative oligomerization interface
identified by examining crystal packing in the ligand-free
CLR:RAMP2 ECD structure (Kusano et al., 2012). The mono-
meric RAMP2 L106R-tethered construct retained selectivity for
AM over CGRP and bound AM(22-52)NH2 essentially identical
to the wild-type tethered fusion in an AlphaScreen competition
binding assay (IC50 5–15 mM) (Figures S1B, S1C, and S1H).
In a cell-based cAMP signaling assay the full-length AM1 recep-
tor with RAMP2 [L106R] exhibited wild-type response to AM
(Figure S1D; Table S4). High-quality crystals of MBP-RAMP2
ECD [L106R]-(GSA)3-CLR ECD grown in the presence of
AM(25-52)NH2 were readily obtained (Figure S1E). Crystals of
MBP-RAMP1 ECD-(GSA)3-CLR ECD grown in the presence
of CGRP(20-37)NH2 diffracted poorly (data not shown); fortu-
nately, high-quality crystals were obtained in the presence
of a high-affinity CGRP analog CGRP(27-37)NH2 [D31, P34,
F35] (Rist et al., 1998) (Figure S1F). In the competition assay,
the CGRP receptor crystallization construct was selective for
CGRP over AM and bound the CGRP analog with higher affinity
(IC500.46 mM) than CGRP(8-37)NH2 (IC502 mM) (Figure S1G).
The CGRP analog also bound the AM1 receptor crystallization
construct with higher affinity than wild-type CGRP but was still
lower affinity than AM (Figure S1H). The crystallized proteins
thus exhibited peptide selectivity consistent with the intact re-
ceptors. The peptides in both crystal forms are antagonist frag-
ments that lack the N-terminal 7TM domain-activating region
(Figure S1I). The CGRP analog will hereafter be referred to as
CGRPmut.
Structures of the CGRPmut-Bound CLR:RAMP1 and
AM-Bound CLR:RAMP2 ECD Heterodimers
Diffraction data for the CGRPmut- and AM-bound receptor
complexes were collected to resolutions of 2.5 and 1.8 A˚,
respectively (Table 1). The structures were solved by molecular
replacement (MR) and refined to good Rwork and Rfree values
(Table 1). Three copies of the tethered CGRP receptor fusion
and one copy of the tethered AM1 receptor fusion were present
in the asymmetric units. Molecule A (Mol A) of the CGRPmut-
bound structure had the best electron density and lowest B-fac-
tors (Table 1); unless otherwise noted the figures use Mol A.
The peptide-bound structures are shown in Figures 1A and 1B.
The mFo-DFc electron density maps for the rebuilt MR models
showed clear, unambiguous density for CGRPmut and AM (Fig-
ures S2A and S2C). MBP sits over the bound peptides, but it
does not appear to alter their binding (Figures S2B and S2D).
Table 1. Data Collection and Refinement Statistics
MBP-RAMP1-
CLR:CGRP(27-37)
NH2 [D31, P34, F35]
MBP-RAMP2-
CLR:AM(25-52)NH2
Data collection
Space group C2 P212121
Cell dimensions
a, b, c 172.81 A˚, 104.62 A˚,
136.48 A˚
71.45 A˚, 84.28 A˚,
115.76 A˚
a, b, g 90, 122.43, 90 90, 90, 90
Resolution 50.0–2.45 A˚
(2.49–2.45 A˚)a
50.0–1.76 A˚
(1.79–1.76 A˚)
Rmerge 0.058 (0.647) 0.068 (0.966)
CC1/2 (0.858) (0.525)
I / sI 24.30 (1.76) 30.13 (1.05)
Completeness 99.8% (98.6%) 99.9% (98.2%)
Redundancy 4.2 (3.9) 7.2 (5.0)
Refinement
Resolution (A˚) 50.0-2.45 A˚ 50.0-1.76 A˚
No. reflections 72,185 66,505
Rwork / Rfree 0.200/0.243 0.157/0.200
Protein molecules/
ASU
3 1
No. atoms (Mol 1/2/3)
MBP 2,885/2,865/2,859 2,898
RAMP1 or RAMP2 705/657/705 721
CLR 805/981/744 805
CGRP or AM 86/86/75 148
Water 70 394
B-factors (Mol 1/2/3)
MBP 71.62/94.58/96.57 37.14
RAMP1 or RAMP2 72.26/101.20/96.41 30.93
CLR 61.60/67.61/88.84 35.75
CGRP or AM 72.24/101.71/81.79 44.55
Water 52.85 39.32
RMS deviations
Bond lengths 0.013 A˚ 0.020 A˚
Bond angles 1.516 1.929
Ramachandran Analysisb
Preferred regions 95.72% 96.8%
Allowed regions 4.04% 3.2%
Outliers 0.24% 0%
aValues in parentheses are for highest-resolution shell.
bAs defined in COOT.
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idues 35–52 (residues 25–34 were disordered) and the majority
of the tethered fusion proteins other than the tethers and 20
residues at the C terminus, which were disordered (Figures
S2B and S2D). The tethers appeared to be longer than neces-
sary, making it unlikely that they altered RAMP-CLR interactions.
CGRPmut and AM occupy similar positions near CLR loops 2,
3, and 4; only their C termini are in proximity to the RAMPs (Fig-ures 1A and 1B). Strikingly, CGRPmut adopts a receptor-bound
conformation devoid of secondary structure. Receptor-bound
AM lacks secondary structure other than one a-helical turn.
Shared turn structures near the peptide C termini similarly posi-
tion the C-terminal residues adjacent to a2 and the a2-a3 loop of
the RAMPs. CGRPmut and AMoccupy the same face of the CLR
ECD as observed for other class B GPCRs with their positions
more similar to that of CRF than PTH (Figure 1C). Helix-breaking
Pro residues are prevalent in the CGRP, AM, and AM2 se-
quences and the four residue segment prior to the C-terminal
residue contains turn-favoring Pro or Gly residues, consistent
with the observed peptide conformations (Figure 1D). The struc-
tures are consistent with our knowledge of the architectures of
the intact receptor complexes. The ECDs are oriented such
that their C termini could continue toward the membrane with
a similar number of residues between the termini visible in the
structures and the predicted start of the TM segments (17 res-
idues for CLR and 8 for the RAMPs). The peptides are oriented
such that their N termini containing the receptor-activating
regions would be directed toward the 7TM domain.
CGRPmut and AM primarily contact CLR, but key RAMP con-
tacts are also formed (Tables S1 and S2). Two key features of the
peptide-binding sites are a hydrophobic patch extending from
the base of CLR loop 4 to loop 3 and a pocket extending from
the base of CLR loop 4 to loop 2 and the RAMPs (Figure 2).
The CLR W72 bulge, previously called the ‘‘Trp shelf’’ (ter Haar
et al., 2010), demarcates patch and pocket. The patch com-
prises the Trp shelf, F92, F95, and Y124. The pockets comprise
the Trp shelf, D70, G71, W121, T122, Y124, and RAMP1 W84
and P85 in the CGRP receptor (Figures 2A and 2B) or RAMP2
R97, E101, E105, and P112 in the AM1 receptor (Figures 2C
and 2D). CGRPmut G33-A36 and AM S48-G51 form type II
b-turns that contact CLR loop 4 in part via hydrogen bonds be-
tween the turn main chain and CLR S117, R119, and W121
side chains (Figures 2B and 2D). The b-turns enable the peptide
C termini to occupy their respective pockets where their amide
groups hydrogen bond with the CLR T122 main chain and their
C-terminal residues pack against the Trp shelf, CLR G71, and
RAMP1 W84 from the a2-a3 loop, which makes hydrophobic
contact with CGRPmut F37 (Figures 2A and 2B), or RAMP2
R97, E101, and E105 from a2, which hydrogen bond with AM
Y52 and K46 (Figures 2C and 2D). Prior to the b-turns CGRPmut
V32 and AM I47 similarly contact the patch, but moving back-
ward thence the peptides diverge in their interactions. CGRPmut
T30 formsmain chain- and side chain-mediated hydrogen bonds
with CLR D94 on loop 3 and contacts the patch via its side chain
methyl group (Figures 2A and 2B). The single helical turn in AM
enables K46 to contact the Trp shelf and pack against AM Y52
and AM P43 and A42 contact the patch (Figures 2C and 2D).
AM K38-A42 form a series of main chain-mediated hydrogen
bonds with the main chain of CLR loop 3 and the side chains
of D94 in loop 3 and T37 on a1 (Figure 2D). For the CGRPmut-
bound structure, 94% of the solvent accessible surface area
(ASA) of the ECD complex buried at the interfacewith the peptide
is from CLR (478 A˚2) and only 6% is from RAMP1 (29 A˚2). More
ASA is buried at the interface with AM, but the majority is still
from CLR, 90% (781 A˚2), whereas RAMP2 contributes only
10% (85 A˚2).Molecular Cell 58, 1–13, June 18, 2015 ª2015 The Authors 3
Figure 1. Peptide-Bound CGRP and AM1
Receptor ECD Heterodimer Structures
(A and B) CGRPmut- and AM-bound complexes in
cartoon representation with disulfide bonds as
sticks and secondary structure elements labeled.
Peptide, CLR, and RAMP terminal residues are
numbered. Peptide side chains are shown as
sticks in the left images but are omitted in the right
images. MBP is not shown. The color scheme is
consistent throughout the figures with carbon
atoms varied in color to distinguish the proteins/
peptides and oxygen, nitrogen, and sulfur atoms in
CPK colors.
(C) Superpositions of the peptide-bound com-
plexes with the PTH:PTH1R ECD (PDB: 3C4M)
and CRF:CRFR1 ECD (PDB: 3EHU) structures.
The receptors are shown as Ca traces and the
peptides as cartoons.
(D) Amino acid sequences of the C-terminal re-
gions of the human CGRP, CGRPmut, AM, and
AM2 peptides. The turn structure region is high-
lighted in gray and Pro residues are in bold. See
also Figures S1 and S2.
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Antagonist-Bound Structures
Superpositions of CGRPmut-bound and ligand-free CLR:
RAMP1 complexes (ter Haar et al., 2010) revealed clamp-like
movement of CLR loops 3 and 4 upon CGRPmut binding, pre-
sumably mediated by the CGRPmut T30-CLR D94 interaction
and b-turn contacts with CLR loop 4 including the CGRPmut
F35-CLR S117 interaction (Figures 3A and 3B). CLR R119 shifts
to accommodate the peptide and RAMP1 F83 rotates away
from CLR loop 4 (Figure 3B). The RAMP1 position relative to
CLR varies in the structures (Figure 3A), but the positions of
the a2-a3 loop and W84, which contacts CGRPmut F37, remain
relatively similar (Figures 3A and 3B).
The CGRPmut-bound structure explains antagonism by the
CGRP receptor-selective small molecule drugs olcegepant and
telcagepant. Superposition of the CGRPmut-bound and drug-
bound structures (ter Haar et al., 2010) indicated that olcegepant4 Molecular Cell 58, 1–13, June 18, 2015 ª2015 The Authorsand telcagepant block key interactions of
the CGRP C-terminal amide and F37 with
the receptor pocket by hydrogen bonding
with the CLR T122 main chain at the base
of the pocket and packing of their piper-
idyl moieties against the Trp shelf and
G71 (Figures 3C and 3D). Olcegepant
also hydrogen bonds with CLR D94,
thereby blocking the CGRP T30-CLR
D94 interaction (Figure 3C). The position
of RAMP1 relative to CLR in the pep-
tide-bound versus drug-bound structures
varies such that the drugs appear to favor
RAMP1 a2 shifting closer to the small
molecule binding sites (Figure 3E), pre-
sumably due to drug-RAMP1 interactions
including packing against W74 (Figures
3C and 3D).Superposition of the AM-bound and ligand-free CLR:RAMP2
complexes (Kusano et al., 2012) revealed minor CLR confor-
mational differences involving the N-terminal region of a1
moving toward AM in the AM-bound state presumably due
to AM-CLR T37 contacts (Figure 3F). CLR loops 3 and 4 do
not move as in the CGRPmut-bound structure and there are
no significant side-chain conformational differences at the
peptide-binding site. The position of RAMP2 relative to CLR
varies in the two structures (Figure 3F), but the ligand-free
RAMP2 position is probably constrained by formation of the
dimer of heterodimers in which the C-terminal end of RAMP2
a2 occupies the peptide-binding site of CLR from the
opposing heterodimer (Figure 3G). Dimerization of the
CLR:RAMP2 ECD heterodimer thus occludes the AM-binding
site, which suggested that the RAMP2 L106R substitution
(at the end of RAMP2 a2) was key to obtaining AM-bound
crystals.
Figure 2. CGRPmut and AM Interactions
with Their Receptor ECD Complexes
(A and C) The peptide-bound structures viewed
with the receptor complexes in molecular surface
representation and the peptides as cartoons with
side chains as sticks.
(B and D) Detailed views with the receptors in
cartoon representation and selected receptor
residues and the peptides as sticks. Red dashes
are hydrogen bonds. Peptide residues are labeled
in (A) and (C) and receptor residues are labeled
in (B) and (D). In (B), CGRPmut residues F27 and
V28 are shown as lines for visualization of the
CGRPmut T30-CLR D94 interaction. See also
Tables S1 and S2.
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To validate the structures, we constructed several Ala substitu-
tion mutants in the CLR and RAMP2 ECDs, and they were
analyzed for their effects on peptide-stimulated cAMP formation
in COS-7 cells. For the CGRP receptor, Ala substitution of CLR
W69, D70, K103, or Y91 significantly reduced CGRP potency,
likely due to the structural roles of these residues (Figure 4, Table
S3). Ala substitution of CLR W72, F92, D94, F95, H114, R119,
W121, T122, or Y124, which are contacted by CGRPmut in the
structure, reduced potency of the full-length CGRP >20-fold
with the CLR D94A mutant being strikingly defective.
For the AM1 receptor, Ala substitution of CLR W72, F92, F95,
W121, or Y124, which are contacted by AM in the structure,
resulted in >40-fold decreases in AM potency (Figure 5A, Table
S4). CLR D94, H114, R119, or T122 mutants were less delete-
rious with 4- to 9-fold decreases in AM potency. Mutation of
RAMP2 E101 yielded 26-fold reduced AM potency (Table S4;
Watkins et al., 2014). Surprisingly, Ala substitution of RAMP2
R97 or E105 did not affect AM signaling potency despite their
contacts with AM (Figure 5B). RAMP2 R97A/E101A and
E101A/E105A double mutants had defects similar to the E101A
singlemutant. These data emphasize that RAMP2E101 provides
the crucial contacts to AM. The Ala substitutions did not signifi-
cantly alter receptor cell surface expression levels other than
reduced AM1 receptor expression with CLR Y124A (Tables S3
and S4).Molecular Cell 58,Peptide Selectivity Determinants
RAMPs may confer selectivity by
providing distinct contacts to the pep-
tides, altering CLR conformation, or a
combination of the two. Superposition of
the CGRPmut- and AM-bound structures
indicated that the RAMPs augment the
peptide-binding site pocket with distinct
residues from their a2-a3 loop and a2
(Figure 6A). RAMP1 W84 in the a2-a3
loop makes hydrophobic contact with
the CGRPmut F37 phenyl ring. This con-
tact would be lost in RAMP2, which has
the smaller F111 at the equivalent posi-
tion. RAMP2 E101 on a2 hydrogen bondswith AM K46 and Y52. The equivalent RAMP1W74 cannot make
these contacts. Two other peptide-proximal RAMP positions
differ: RAMP1 F83/RAMP2 G110 on the a2-a3 loop and
RAMP1 A70/RAMP2 R97 on a2 (Figure 6B). The F83/G110 posi-
tion is close to CLR loop 4 and the R119 side chain that has
different conformations in the two structures. RAMP2R97,which
participates in the hydrogen bond network near AM Y52, would
sterically clash with a Trp at position 111. The small A70 in
RAMP1 avoids a clash with W84.
The positions of RAMP1 and RAMP2 relative to CLR differ in
the two structures and the RAMPs elicit subtly different CLR con-
formations (Figure 6A). Equivalent RAMP1/2 Ca positions at the
end of a2 differ by 3 to 4.5 A˚ such that RAMP2 a2 is closer to
the peptide-binding site than RAMP1 a2. A similar 3 to 4.5 A˚
displacementof theRAMP1/2a3helices is accompaniedbyshifts
in thepositionof theC-terminal endofCLRa1 (Figures6Aand6B).
The RAMPs and CLR a1 appear to move somewhat as a unit
relative to the remainder of CLR, which is also evident in the com-
parisons of the peptide-bound structures to the ligand-free and
small molecule antagonist-bound structures (Figures 3A, 3E,
and 3F). The subtly differentCLR loop2positions in the structures
may reflect RAMP-dependent differences at the interface with
CLR a1 propagated to loop 2 via CLRW69 (Figures 6A and 6B).
To explore the contribution of RAMP binding site augmen-
tation to selectivity, we constructed RAMP ‘‘swap’’ mutants
in which the four variable residue positions near the peptide
C termini were reciprocally exchanged between RAMP1 and1–13, June 18, 2015 ª2015 The Authors 5
Figure 3. Comparisons of the CGRPmut- and AM-Bound Structures to Ligand-free and Small Molecule Antagonist-Bound Structures
(A) CGRPmut-bound complexes from Mol A and Mol C were aligned with four independent ligand-free CLR:RAMP1 complexes (PDB: 3N7P) based on the CLR
positions. Mol B of the CGRPmut-bound structure was omitted because crystal packing altered its conformation. Receptors are shown as Ca traces. Arrows
denote the directions of loop movements upon CGRPmut binding. The double-headed arrow highlights variability in the RAMP1 position relative to CLR.
(B) Detailed view of differences between the CGRPmut-bound and ligand-free states of the CLR:RAMP1 ECD complex. CGRPmut F27 and V28 are omitted for
clarity.
(C and D) Superposition of CGRPmut-bound and olcegepant-bound (PDB: 3N7S) (C) or telcagepant-bound (PDB: 3N7R) (D) structures aligned based on the CLR
positions. The peptide and small molecules are shown as sticks.
(E) Superpositions of the CGRPmut-bound structures with two independent olcegepant-bound complexes and a single telcagepant-bound complex based on
the CLR positions. The arrow indicates the direction of movement of RAMP1 from the small molecule antagonist-bound to CGRPmut-bound states.
(F) Superposition of the AM-bound and ligand-free (PDB: 3AQF) CLR:RAMP2 ECD structures aligned based on the CLR positions. Receptors are shown as Ca
traces and selected receptor and peptide residues as sticks. Arrows indicate directions of movement from ligand-free to AM-bound states.
(G) Putative dimer of ligand-free CLR:RAMP2 ECD heterodimers with the AM-bound CLR:RAMP2 ECD [L106R] heterodimer superimposed based on the CLR
positions. The receptors and peptide are in cartoon representation and residues L/R106 are in space-filling representation. The arrow indicates the shift of RAMP2
in the AM-bound structure as compared to the ligand-free state. The top image is oriented similar to that in (F), right image.
Please cite this article in press as: Booe et al., Structural Basis for Receptor Activity-Modifying Protein-Dependent Selective Peptide Recognition by a G
Protein-Coupled Receptor, Molecular Cell (2015), http://dx.doi.org/10.1016/j.molcel.2015.04.018RAMP2 (A70/R97, W74/E101, F83/G110, and W84/F111) and
we tested their response to CGRP and AM in the cAMP assay
(Figures 6C and 6D). The clearest effect was one of a modest
decrease in cognate ligand potency. Accordingly, CGRP po-6 Molecular Cell 58, 1–13, June 18, 2015 ª2015 The Authorstency decreased 10-fold at the CGRP receptor that included
the RAMP1 mutant with RAMP2 residues and AM potency
decreased50-fold in the AM1 receptor with the RAMP2mutant
that contained RAMP1 residues. Thus, swapping these RAMP
Figure 4. Validation of the CGRPmut-Bound ECDHeterodimer Structure for the Intact CGRP Receptor Transiently Expressed in COS-7 Cells
Concentration-response curves for each of the CLR alanine substitution mutants tested with haCGRP in cAMP signaling assays. Data are represented as
mean ± SEM. See also Table S3.
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but the differing RAMP1/2 positions probably complicated the
experiment.
We turned to peptide swap experiments to test whether recip-
rocal exchanges of the C-terminal residues of minimal ECD
complex-binding CGRP and AM peptides (Moad and Pioszak,
2013) could exchange their receptor selectivity. In the competi-
tion AlphaScreen assay, CGRP(27-37)NH2 [F37Y] retained the
ability to bind the CGRP receptor ECD complex (Figure 6E)
and did not gain AM-like affinity for the AM1 receptor ECD com-
plex (Figure 6H). CGRPmut [F37Y] retained CGRP receptor ECD
complex binding (Figure 6F) and gained the ability to bind the
AM1 receptor ECD complex as strongly as AM (Figure 6I).
AM(37-52)NH2 [Y52F] exhibited significantly diminished binding
to the AM1 receptor ECD complex (Figure 6J) but did not gain
increased affinity for the CGRP receptor ECD complex (Fig-
ure 6G). These results suggested that the RAMP2 E101-AM
Y52 hydrogen bond is a key contributor to AM1 receptor selec-
tivity, whereas Phe as the peptide C-terminal residue is insuffi-
cient to confer CGRP receptor selectivity.DISCUSSION
RAMPs are an important class of accessory membrane pro-
teins that modulate GPCR pharmacology. The CGRPmut-bound
CLR:RAMP1 ECD and AM-bound CLR:RAMP2 ECD structures
presented here expand our understanding of the mechanisms
by which peptides can bind to class B GPCRs and increase
our understanding of how RAMPs enable peptide selectivity.
The engineered tethered ECD fusion proteins used for crystalli-
zation exhibited the same peptide selectivity rank order as the
intact receptors, which indicated that they are valid reagents
for studying selective peptide binding. The purified proteins
bound their respective peptides with apparent affinities in the
low mM range (Figures S1C, S1G, and S1H), which are lower
than the affinities of the agonist peptides for intact receptors
but typical for truncated peptides at class B GPCR ECDs (Pal
et al., 2010; Parthier et al., 2007; Pioszak and Xu, 2008).
The oligomeric states of CLR:RAMP complexes has been a
source of debate with evidence for 1:1, 2:1, and 2:2 CLR:RAMP
stoichiometries (He´roux et al., 2007; Hill and Pioszak, 2013;Molecular Cell 58, 1–13, June 18, 2015 ª2015 The Authors 7
Figure 5. Validation of the AM-Bound ECD Heterodimer Structure for the Intact AM1 Receptor Transiently Expressed in COS-7 Cells
Concentration-response curves for each of the CLR (A) or RAMP2 (B) alanine substitution mutants tested with hAM in cAMP signaling assays. Data are
represented as mean ± SEM. See also Table S4.
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2013a). Dimerization of the purified CLR:RAMP2 ECD hetero-
dimer to form a 2:2 complex may be an artifact because the
RAMP2 L106R mutation prevented oligomerization yet did not
affect AM1 receptor function (Figure S1). Occlusion of the AM-
binding site by dimerization explains our inability to measure
AM binding to the tethered RAMP2-CLR ECD fusion protein in
an assay using mM receptor concentration, whereas AM binding
was readily measured in an assay using nM receptor concentra-
tion where the dimeric species was likely not significantly pre-
sent (Moad and Pioszak, 2013). He´roux et al. (2007) provided
evidence for a homo-oligomer of CLR with a single RAMP1 as
the functional CGRP receptor in cells. We cannot rule out a
role for higher-order oligomerization in the function of the intact
receptors, but the structures indicate that the 1:1 heterodimers
are sufficient to bind peptides.
The CGRPmut and AM peptides adopted receptor-bound
conformations different from typical a-helical class BGPCRpep-
tide ligands. CGRPmut and AM are characterized by a shared
turn structure that positions their C-terminal residue to occupy8 Molecular Cell 58, 1–13, June 18, 2015 ª2015 The Authorsthe pocket near the RAMP. Previous studies indicated the pres-
ence of turns in the C-terminal region of CGRP (and an absence
of a-helix in this area), but how this region interacted with the
receptor was unclear (Carpenter et al., 2001; Watkins et al.,
2013b). Prior to the turns, the peptides diverge in their structure
and interactions with CLR, but they contact the same area of
CLR with little or no peptide secondary structure. NMR struc-
tures of CGRP and AM suggested that a-helix is restricted
to residues 8-18/22-34 of these peptides (Boulanger et al.,
1995; Breeze et al., 1991; Pe´rez-Castells et al., 2012; Watkins
et al., 2013a) and indeed the C-terminal regions of both contain
helix-breaking Pro residues (Figure 1D). Accordingly, the lack of
substantial helical content in the bound peptide fragments is
consistent with what is known about the structures of the full-
length peptides. A turn structure and paucity of a-helicity may
be a general feature of the receptor ECD-binding portions of
CT family peptides.
The CGRPmut and AM binding modes are consistent with
peptide mutagenesis studies. CGRP T30, V32, and F37 and
the C-terminal amide were important for binding purified
Figure 6. Peptide Selectivity Determinants for CLR:RAMP1/2 Complexes
(A) Superposition of the CGRPmut- and AM-bound ECD heterodimers aligned based on the CLR positions. The receptors and peptides are in cartoon repre-
sentation with selected residues as sticks in the left image. In the right image, the receptors are Ca traces and the peptide cartoons were omitted for clarity.
Arrows indicate directions of movement of CLR a1 and loop 2 and RAMP a2 and a3 from the CGRPmut/RAMP1-bound state to the AM/RAMP2-bound state. Red
dashes are hydrogen bonds.
(B) Detailed view of the aligned CGRPmut- and AM-bound complexes with selected residues as sticks and the receptors as Ca traces. The arrow highlights the
shift of the C-terminal region of CLR a1 from the CGRPmut/RAMP1- to AM/RAMP2-bound states.
(C and D) Concentration-response curves for the CGRP and AM1 receptors with the RAMP1 (A70R, W74E, F83G, W84F) and RAMP2 (R97A, E101W, G110F,
F111W) quadruple ‘‘swap’’ mutants tested with haCGRP and hAM in cAMP assays in COS-7 cells. The cell surface expression was: RAMP1 quad 116.4 ± 5.25
(n = 4) % WT, RAMP2 quad 73.7 ± 9.52 (n = 4) % WT p < 0.01 by one-way ANOVA followed by Dunnett’s test for the RAMP2 quad mutant.
(E–J) Competition AlphaScreen assays with purified receptor ECD heterodimer proteins and the indicated competitor ‘‘swap’’ peptides. (E)–(G) are for the MBP-
RAMP1-(GSA)3-CLR-H6 protein with biotin-CGRP (100 nM each) and (H)–(J) are for the MBP-RAMP2[L106R]-(GSA)3-CLR-H6 protein with biotin-AM (100 nM
each). The binding data are representative of at least three independent experiments each performed in duplicate. The error bars represent the SEM of the
experiment. Determinable pIC50 values were as follows: (F), CGRPmut 6.79 ± 0.10 and CGRPmut [F37Y] 6.24 ± 0.09; (G), CGRP(8-37) 5.01 ± 0.04; (H), AM(22-52)
4.92 ± 0.16; (I), AM(22-52) 4.84 ± 0.09 and CGRPmut [F37Y] 4.79 ± 0.07; (J), AM(37-52) 5.00 ± 0.11.
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receptor (Carpenter et al., 2001; Rist et al., 1998; Watkins
et al., 2013b). Modified CGRP peptides as short as 30–37 main-
tained the ability to bind the receptor (Carpenter et al., 2001),
consistent with this region providing most of the contacts.
Increased affinity of CGRPmut over that of CGRP can be ex-
plained by their differences in the turn region (Figure 1D). P34 fa-
vors b-turn formation better than S34 and F35 provides better
hydrophobic contact to CLR loop 4 than K35. AM P43, K46,
I47, G51, Y52, and the C-terminal amide were most critical for
binding purified CLR:RAMP2 ECD and intact AM1 receptor,
and truncation beyond residue 38 diminished binding eventhough the K38-V41 side chains were not important (Moad and
Pioszak, 2013; Watkins et al., 2013a).
Mapping the receptor mutagenesis data (Figures 4 and 5) onto
the surface of the receptor structures (Figures 7A and 7B) sug-
gests that CGRP binds in a similar manner to CGRPmut and
that the structures are good models for full-length CGRP and
AM binding to intact receptors. Mutation of CLR residues that
form the shared binding site diminished CGRP and AM po-
tencies, and the effects of some of the mutations were similar
for both peptides (e.g., F92). Noteworthy divergent effects of
several mutations support the differences in the structures.
CLR D94 was far more important for CGRP action than AM,Molecular Cell 58, 1–13, June 18, 2015 ª2015 The Authors 9
Figure 7. Summary of Peptide Recognition and Selectivity Determinants for CLR:RAMP1-3 Complexes
(A and B) Structures of the CGRPmut- and AM-bound CLR:RAMP1/2 ECD heterodimers with the surface of receptor residues colored according to their effect on
CGRP (A) or AM (B) signaling potency when mutated to alanine. Color coding signifies the extent of reduced signaling potency at intact receptor complexes in
cells compared to wild-type as indicated by the inset legend. RAMP1 W84A data are from Moore et al. (2010) (34-fold reduced potency).
(C) Model for RAMP3 binding site augmentation. A homology model of the AM-bound CLR:RAMP3 ECD complex (Supplemental Experimental Procedures) was
superimposed with the CGRPmut-bound CLR:RAMP1 and AM-bound CLR:RAMP2 ECD structures based on the CLR positions. Only the RAMP3 subunit from
the homology model is shown and RAMP2 is omitted. The receptors are shown as Ca traces and selected residues as sticks.
(D) Amino acid sequence alignments for RAMP1-3 from the indicated species showing the a2 and a2-a3 loop regions that augment the peptide-binding site.
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and its less important role in contacting the AM main chain.
CLR R119A diminished the potency of CGRP much more than
that of AM, which may reflect an important role for the different
R119 conformations observed in the two structures. CLR
W72A was more deleterious for AM action than CGRP, which
is consistent with the greater number of AM contacts to CLR
W72 as compared to CGRP.
RAMP1 W84 and RAMP2 E101 were previously identified as
key residues for CGRP and AM function, respectively (Moore
et al., 2010; Watkins et al., 2014). These data are explained by
how these residues augment the binding site pocket (Figures
7A and 7B). Apparently, packing of the CGRP F37 and AM Y52
phenyl rings against the CLR Trp shelf and G71 is insufficient
for strong binding. RAMP1 W84 or RAMP2 E101 is required to
complete the pocket to enable strong ‘‘anchoring’’ of the peptide
C termini. RAMP2 R97 and E105 also augment the pocket, but
the R97A and E105A mutants did not diminish AM potency.
These data along with the peptide swap data indicate that the
RAMP2 E101-Y52 hydrogen bond is the crucial AM anchoring
contact. Ionic interactions of AM K46 and RAMP2 E101/E105
do not appear to be significant. The main role of AM K46 thus10 Molecular Cell 58, 1–13, June 18, 2015 ª2015 The Authorsappears to be intramolecular packing against Y52 and contact-
ing the Trp shelf.
Distinct RAMP binding site augmentation clearly contributes
to peptide selectivity (Figure 6). RAMP2 E101 favors AM binding
because it can hydrogen bond with Y52 and RAMP2 F111 dis-
courages CGRP binding because it is too small to contact the
F37 phenyl ring. Indeed, the F37Y swap in CGRPmut conferred
strong affinity for the AM1 receptor ECD complex and the Y52F
swap in AM(37-52)NH2 significantly diminished its binding. The
lack of Glu at RAMP1 position 74 would disfavor strong AMbind-
ing. RAMP1 W84 enables strong CGRP binding by contacting
F37, but this contact alone is apparently insufficient for selec-
tivity because AM(37-52)NH2 [Y52F] did not gain affinity for the
CGRP receptor ECD complex.
Modeling the AM-bound AM2 receptor ECD complex (Supple-
mental Experimental Procedures) suggests that RAMP3 aug-
ments the binding site as a RAMP1-2 hybrid (Figure 7C).
RAMP3 E74, which is equivalent to RAMP2 E101, would favor
AM binding by hydrogen bonding with Y52. RAMP3 W84, which
is equivalent to RAMP1 W84, could contact the AM Y52 and
CGRP F37 phenyl rings, thereby explaining diminished potency
of both peptides at the AM2 receptor with RAMP3W84A andwhy
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(Watkins et al., 2014). The key RAMP residues proposed as
selectivity determinants are conserved across species: W84
and a lack of Glu at position 74 in RAMP1, E101 and F or Y at po-
sition 111 in RAMP2, and E74 and W84 in RAMP3 (Figure 7D). A
small amino acid is conserved at position 70 in RAMP1/3, which
would avoid steric clash with W84. Notably, the lack of conser-
vation of RAMP2 R97 and E105 is consistent with the mutagen-
esis data that indicated that these residues are not critical for AM
signaling.
Previous RAMP single swap mutant studies supported the
importance of Glu at position 74/101 as a determinant for AM
selectivity. RAMP1 W74E had no effect on CGRP potency but
increased AM potency at the CGRP receptor (Qi et al., 2008,
2011). RAMP3 E74W decreased AM potency at the AM2 recep-
tor, while having a negligible effect on CGRP potency (Hay et al.,
2006; Qi et al., 2008, 2011). More extensive quadruple swap
mutants in this study failed to exchange the pharmacological
profiles, but these experiments are complicated by the different
RAMP positions relative to CLR and variable RAMP effects on
CLR conformation.
The failure of the CGRP and AM peptide C-terminal residue
swaps to exchange their receptor preferences (Figure 6) strongly
suggests that RAMP binding site augmentation alone is insuffi-
cient to account for selectivity. Thus, the subtle differences in
CLR conformation in the two structures may also be important
for selectivity. RAMP-induced changes in CLR R119 side-chain
conformation and/or subtle shifting of loop 2 may sufficiently
alter the pocket to favor one peptide over the other. Future
studies will be required to determine to what extent such allo-
stery contributes to selectivity. Peptide selectivity determinants
may also exist in portions of the receptors that were not ad-
dressed in this study.
In summary, the structures presented here provide the first
structural views of any accessory membrane protein modulating
GPCR ligand binding and may provide a basis for understand-
ing modulation of other GPCRs by accessory proteins. Our
data indicate that RAMPs determine peptide selectivity of
CLR through a combination of binding site augmentation and
alteration of CLR conformation. It is striking that relatively minor
differences in RAMP-specific peptide contacts and subtle
RAMP-induced changes in CLR conformation lead to such
profoundly different pharmacological profiles. Of practical
value, the structures may inform rational drug design targeting
CLR:RAMP complexes with clinical relevance for migraine
headache and cardiovascular disorders. Lastly, the MBP-teth-
ered ECD fusion protein approach to crystallization should facil-
itate structural studies of other CT family peptides bound to
their respective receptor ECD complexes, which will enable a
more complete understanding of how RAMPs modulate both
CLR and CTR.EXPERIMENTAL PROCEDURES
Protein Production and Characterization and Peptides
Plasmid construction, mutagenesis, protein expression, purification, and the
AlphaScreen peptide-binding assay were as previously described with minor
modifications to the AlphaScreen assay (Hill and Pioszak, 2013; Moad andPioszak, 2013). Synthetic peptides were from RS Synthesis, Bachem, or were
synthesized in-house. Details are in Supplemental Experimental Procedures.
Crystallization, Structure Solution, and Homology Modeling
The tethered MBP-RAMP1 ECD-CLR ECD and MBP-RAMP2 ECD [L106R]-
CLR ECD proteins were complexed with CGRP(27-37)NH2 [D31, P34, F35]
or AM(25-52)NH2 and crystallized with a reservoir solution of 22% PEG3350,
8% Tacsimate (pH 6.0) for the CGRP receptor complex or 19% PEG3350,
0.1 M Tris-HCl (pH 8.3), 225 mM sodium acetate, and 20% ethylene glycol
for the AM1 receptor complex. Diffraction data collected at the APS synchro-
tron were processed with HKL2000 (Otwinowski and Minor, 1997) and the
CCP4 suite (Winn et al., 2011). The structures were solved by molecular
replacement with Phaser (McCoy et al., 2007), rebuilt with COOT (Emsley
et al., 2010), and refined with REFMAC5 (Murshudov et al., 1997). Details
and homology modeling are in Supplemental Experimental Procedures.
Cell-Based Assays
Transfection of COS-7 cells, cAMP assay, ELISA for cell surface expression,
and data analysis were as previously described (Barwell et al., 2010; Watkins
et al., 2014).
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